Posts

Fulcrum scraps SCD program, considers options after FDA takes hard line on safety risks

on

Kezar Initiates Strategic Review After FDA Setback; Taysha Regains Full Rights to Rett Syndrome Program as Astellas Agreement Ends

on

Galapagos Considers Sale of Cell Therapy Unit in Ongoing Strategic Overhaul

on

Leap Therapeutics Slashes 75% of Workforce, Ends Clinical Trial, Considers Strategic Options

on

Mural risks going to the wall as IL-2 flop triggers 90% staff reduction, hunt for strategic alternatives

on

Ironwood Pharmaceuticals' Stock Plummets Following Layoffs and FDA Setback for Apraglutide

on

Navigating Challenges: Keros and Tempest Aim to Stabilize and Strategize for Growth

on

Lava cuts jobs by 30% after key drug discontinued

on

Viracta Therapeutics Shuts Down Operations, Lays Off Entire Workforce

on

Turnstone Biologics Discontinues Final Clinical Program, Initiates Strategic Review Amid Financial Constraints

on

Sage Therapeutics Rejects Biogen's Acquisition Bid, Initiates Strategic Review

on